ADM and heart failure: The increasing evidence indicating the protective properties of ADM on reducing endothelial permeability and improving endothelial stability and microcirculation, thereby reducing organ damage, as well as its anti-microbial activity, has prompted several clinical trials in sepsis and heart failure to investigate the potential therapeutic use of antibodies, such as adrecizumab targeting ADM.